Lessons from the PROTECT-CH COVID-19 platform trial in care homes
(2024)
Journal Article
Bath, P. M., Ball, J., Boyd, M., Gage, H., Glover, M., Godfrey, M., Guthrie, B., Hewitt, J., Howard, R., Jaki, T., Juszczak, E., Lasserson, D., Leighton, P., Leyland, V., Shen Lim, W., Logan, P., Meakin, G., Montgomery, A., Ogollah, R., Passmore, P., …Gordon, A. L. (in press). Lessons from the PROTECT-CH COVID-19 platform trial in care homes. Health Technology Assessment,
Professor ALAN MONTGOMERY's Outputs (8)
Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT (2024)
Journal Article
Wyatt, L. A., Bradshaw, L. E., Brown, S. J., Haines, R. H., Montgomery, A. A., Perkin, M. R., Sach, T. H., Lawton, S., Flohr, C., Ridd, M. J., Chalmers, J. R., Brooks, J., Swinden, R., Mitchell, E. J., Tarr, S., Jay, N., Thomas, K. S., Allen, H., Cork, M. J., Kelleher, M. M., …Williams, H. C. (2024). Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT. Health Technology Assessment, 28(29), 1-116. https://doi.org/10.3310/rhdn9613Background
Atopic eczema is a common childhood skin problem linked with asthma, food allergy and allergic rhinitis that impairs quality of life.
Objectives
To determine whether advising parents to apply daily emollients in the first year can... Read More about Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.
Prevalence and risk factors for milk allergy overdiagnosis in the BEEP trial cohort (2024)
Journal Article
Allen, H. I., Wing, O., Milkova, D., Jackson, E., Li, K., Bradshaw, L. E., Wyatt, L., Haines, R., Santer, M., Murphy, A. W., Brown, S. J., Kelleher, M., Perkin, M. R., Jay, N., Smith, T. D. H., Moriarty, F., Montgomery, A. A., Williams, H. C., & Boyle, R. J. (2025). Prevalence and risk factors for milk allergy overdiagnosis in the BEEP trial cohort. Allergy, 80(1), 148-160. https://doi.org/10.1111/all.16203Background: Cow's milk allergy (CMA) overdiagnosis in young children appears to be increasing and has not been well characterised. We used a clinical trial population to characterise CMA overdiagnosis and identify individual‐level and primary care pr... Read More about Prevalence and risk factors for milk allergy overdiagnosis in the BEEP trial cohort.
Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers (Hand-2): study protocol for a randomised controlled trial (2024)
Journal Article
Harrison, S., Ogollah, R., Hollingworth, W., Mills, N., Karantana, A., Blazeby, J., Montgomery, A., Shafayat, A., Jarrett, H., & Davis, T. (2024). Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers (Hand-2): study protocol for a randomised controlled trial. Trials, 25(1), Article 398. https://doi.org/10.1186/s13063-024-08003-1Background: Dupuytren’s contractures (DC) are fibrous cords under the skin of the hand that cause one or more fingers to curl gradually and irreversibly towards the palm. These contractures are usually painless but can cause a loss of hand function.... Read More about Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers (Hand-2): study protocol for a randomised controlled trial.
Choosing and evaluating randomisation methods in clinical trials: a qualitative study (2024)
Journal Article
Bruce, C. L., Iflaifel, M., Montgomery, A., Ogollah, R., Sprange, K., & Partlett, C. (2024). Choosing and evaluating randomisation methods in clinical trials: a qualitative study. Trials, 25(1), Article 199. https://doi.org/10.1186/s13063-024-08005-zBackground: There exist many different methods of allocating participants to treatment groups during a randomised controlled trial. Although there is research that explores trial characteristics that are associated with the choice of method, there is... Read More about Choosing and evaluating randomisation methods in clinical trials: a qualitative study.
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2024)
Journal Article
RECOVERY Collaborative Group, Sandercock, P., Darbyshire, J., DeMets, D., Fowler, R., Lalloo, D., Munavvar, M., Warris, A., Wittes, J., Cradduck-Bamford, A., Barton, J., Basoglu, A., Brown, R., Brudlo, W., Denis, E., Fletcher, L., Howard, S., Taylor, K., Cui, G., Goodenough, B., …Local Clinical Centre staff (for the RECOVERY Collaborative Group). (in press). Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 15, Article 924. https://doi.org/10.1038/s41467-023-43644-xDimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOV... Read More about Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
[TEMPORARILY RENAMED] Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial (2024)
Journal Article
Faust, S. N., Jones, C. E., Staplin, N., Whittaker, E., Jaki, T., Juszczak, E., Spata, E., Wan, M., Bamford, A., Dmitri, P., Finn, A., Furness, J., Ramanan, A. V., Gale, C., Cathie, K., Drysdale, S. B., Bernatoniene, J., Murray, C., Roehr, C. C., Fleming, P. F., …Haynes, R. (2024). [TEMPORARILY RENAMED] Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health,Background
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY tri... Read More about [TEMPORARILY RENAMED] Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial (2024)
Journal Article
RECOVERY Collaborative Group, Faust, S. N., Haynes, R., Jones, C. E., Staplin, N., Whittaker, E., Jaki, T., Juszczak, E., Spata, E., Wan, M., Bamford, A., Dimitri, P., Finn, A., Furness, J., Ramanan, A. V., Gale, C., & Montgomery, A. (2024). Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8(3), 190-200. https://doi.org/10.1016/S2352-4642%2823%2900316-4Background
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial... Read More about Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.